Back HIV/AIDS

HIV / AIDS

CDC Reports Probable Case of HIV Transmission Linked to Lesbian Sex

A woman in Texas who reported no other risk factors appears to have contracted HIV through sex with a female partner who was not on antiretroviral therapy, according to a report in the March 14, 2014, edition of the CDC's Morbidity and Mortality Weekly Report.

alt

CROI 2014: Disparities in Viral Suppression in Washington, DC [VIDEO]

A majority of people with HIV in Washington, DC, were able to achieve and maintain undetectable HIV viral load on antiretroviral therapy, but disparities in viral suppression exist with regard to race, sex, social, and economic factors, researchers reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston.

alt

CROI 2014: Early Treatment Reduces Viral Reservoirs but Does Not Prevent Rebound

Antiretroviral therapy started during the first several days after infection limited dissemination of an HIV-like virus throughout the body and establishment of cellular and tissue reservoirs in monkeys, though it did not prevent the virus from coming back after stopping treatment, according to research presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston.

alt

CROI 2014: Heart Attack Risk May Be Falling for People with HIV -- But Not for Women

A number of studies at last week’s 21st Conference on Retroviruses and Opportunistic Infections in Boston examined whether people with HIV have an elevated risk of heart attack and other manifestations of cardiovascular disease  (CVD). They came to different conclusions about whether having HIV is in itself a cardiovascular risk factor.

alt

CROI 2014: Early Antiretroviral Therapy May Limit Gut Damage and Immune Activation

Starting antiretroviral therapy (ART) at the earliest stage of HIV infection can help prevent immune cell dysregulation that contributes to destruction of the gut lining and promotes systemic immune over-activation, according to a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston.

alt

CROI 2014: Raltegravir Has Edge Over 2 HIV Protease inhibitors in 3-Drug Comparison

In a head-to-head comparison of 3 drugs presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI) last week in Boston, the integrase inhibitor raltegravir (Isentress) proved to be superior, in terms of the overall likelihood of treatment failure, when compared to 2 ritonavir-boosted protease inhibitors, atazanavir (Reyataz) and darunavir (Prezista).

alt

CROI 2014: HIV Incidence at Record High Among Young Gay Black Men in Southern U.S.

HIV incidence in young black gay men in Atlanta is running at 12.1% a year -- one of the highest figures for HIV incidence ever recorded in a population in the resource-rich world -- according to research presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston. Lack of health insurance, incarceration, and partner choice were all implicated as causes.

alt